Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 2 (2005), Issue 10 (October)

1. Differential expression of laminin isoforms in ovarian epithelial carcinomas suggesting different origin and providing tools for differential diagnosis.
   J Histochem Cytochem, 53(10): 1293-300. [Abstract] [Full-text]
2. Phototoxicity of Hemoporfin to ovarian cancer.
   Biochem Biophys Res Commun, 337(1): 127-32. [Abstract] [Full-text]
3. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas.
   Cancer Immunol Immunother, 54(12): 1200-13. [Abstract] [Full-text]
4. Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells.
   Endocrinology, 146(11): 4951-60. [Abstract] [Full-text]
5. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo.
   J Natl Cancer Inst, 97(20): 1516-24. [Abstract] [Full-text]
6. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
   JAMA, 294(15): 1925-33. [Abstract] [Full-text]
7. Improved survival with clinical guidelines? Evaluation of a quality register linked to clinical guidelines for ovarian cancer in the western health care region in Sweden between 1 September 1993 and 1 June 1998.
   Acta Obstet Gynecol Scand, 84(11): 1113-8. [Abstract] [Full-text]
8. Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells.
   Carcinogenesis, 26(11): 1978-87. [Abstract] [Full-text]
9. Expression of acyl-CoA synthetase 5 in human endometrium and in endometrioid adenocarcinomas.
   Histopathology, 47(5): 501-7. [Abstract] [Full-text]
10. Resource utilization for ovarian cancer patients at the end of life: how much is too much?
    Gynecol Oncol, 99(2): 261-6. [Abstract] [Full-text]
11. Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use.
    Gynecol Oncol, 99(2): 462-71. [Abstract] [Full-text]
12. Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population.
    Cancer, 104(9): 1849-53. [Abstract] [Full-text]
13. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma.
    Cancer, 104(9): 1924-30. [Abstract] [Full-text]
14. Sister Joseph's Nodule and pneumatosis: a rare presentation of ovarian cancer.
    Gynecol Oncol, 99(2): 517-8. [Abstract] [Full-text]
15. Who should operate on patients with ovarian cancer? An evidence-based review.
    Gynecol Oncol, 99(2): 447-61. [Abstract] [Full-text]
16. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors.
    Gynecol Oncol, 99(2): 427-31. [Abstract] [Full-text]
17. Ovarian malignant melanoma: unusual presentation of a solitary metastasis.
    Gynecol Oncol, 99(2): 412-4. [Abstract] [Full-text]
18. Patient-provider communication and perceived control for women experiencing multiple symptoms associated with ovarian cancer.
    Gynecol Oncol, 99(2): 404-11. [Abstract] [Full-text]
19. Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
    Gynecol Oncol, 99(2): 472-6. [Abstract] [Full-text]
20. Prevention of adhesion formation after radical oophorectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier.
    Gynecol Oncol, 99(2): 301-8. [Abstract] [Full-text]
21. The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas.
    Gynecol Oncol, 99(2): 278-86. [Abstract] [Full-text]
22. Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival.
    Gynecol Oncol, 99(2): 320-6. [Abstract] [Full-text]
23. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
    Gynecol Oncol, 99(2): 267-77. [Abstract] [Full-text]
24. Surgical care of elderly women with ovarian cancer: a population-based perspective.
    Gynecol Oncol, 99(2): 352-7. [Abstract] [Full-text]
25. Serous psammocarcinoma of the ovary: an unusual finding.
    Gynecol Oncol, 99(2): 510-1. [Abstract] [Full-text]
26. Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer.
    Gynecol Oncol, 99(2): 287-93. [Abstract] [Full-text]
27. Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy.
    Gynecol Oncol, 99(2): 343-7. [Abstract] [Full-text]
28. CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma.
    Gynecol Oncol, 99(2): 493-6. [Abstract] [Full-text]
29. Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology.
    Gynecol Oncol, 99(2): 367-75. [Abstract] [Full-text]
30. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes.
    Gynecol Oncol, 99(2): 294-300. [Abstract] [Full-text]
31. Yolk sac tumor of the ovary during pregnancy: a case report.
    Gynecol Oncol, 99(2): 497-9. [Abstract] [Full-text]
32. Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026.
    Br J Cancer, 93(9): 1011-8. [Abstract] [Full-text]
33. Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI.
    Br J Cancer, 93(9): 979-85. [Abstract] [Full-text]
34. Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.
    Int J Cancer, 117(6): 1049-54. [Abstract] [Full-text]
35. Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer.
    Oncogene, 24(47): 7084-93. [Abstract] [Full-text]
36. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.
    J Clin Oncol, 23(31): 7919-26. [Abstract] [Full-text]
37. Unique gene expression profile based on pathologic response in epithelial ovarian cancer.
    J Clin Oncol, 23(31): 7911-8. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.